Molecular Partners AG
🇨🇭XSWX.MOLNSwitzerlandNot reported
PriceCHF 3.22-0.18 (-5.29%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 6
- Medium: 1
- Low: 0
Daily return: an extreme move up, far outside its trailing 60-day range
EBITDA margin: collapsed against the prior period
EBIT margin: collapsed against the prior period
Free cash flow margin: collapsed against the prior period
Gross margin: collapsed against the prior period
Free with a Finzer account.
Profile
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0256379097
- CUSIP
- Not reported
Company
- Employees
- 158
- Headquarters
- Schlieren, Germany
Market
- Shares outstanding
- 37.4M
- Market cap
- CHF 120.4M
Highlights
- Market cap
- CHF 127.13M
- EPS LTM
- -CHF 1.73
- P/E LTM
- -2.13
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 681K-91.34%down year on year
- Net income
- -CHF 64.81M-12.46%down year on year
- Gross margin
- -62.26%+88.58%up year on year
- Free cash flow
- -CHF 57.6M+2.65%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Molecular Partners AG is listed on SIX Swiss Exchange (Switzerland) under the ticker MOLN. Its market capitalisation is CHF 120.4M, from 37.4M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 2.66 and CHF 3.96, and the last close of CHF 3.22 sits 43% of the way up that range. The company is headquartered in Schlieren, Germany, and employs about 158 people. The same company also trades as 0QXX on London Stock Exchange, and as 6ML on Stuttgart Stock Exchange.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.